Exact Sciences Corporation EXAS NASDAQ

Exact Sciences Corporation (EXAS) reported total assets of $5.86B and total liabilities of $3.46B for fiscal year 2025, resulting in total equity of $2.4B.

The company held $964.71M in cash and short-term investments. Total debt stood at $2.52B, with net debt of $1.57B. The Debt-to-Equity (D/E) ratio was 1.05 (moderate).

Current ratio is 2.43, indicating strong short-term liquidity. Interest coverage is -3x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (71/100) — Total assets $5.86B and equity $2.4B support the company's competitive scale
• VALUE (35/100) — Debt-to-Equity 1.05 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 36/100 with 1/7 criteria passed.

TMO

Thermo Fisher Scientific Inc.

$527.22

+2.53%

DHR

Danaher Corporation

$198.61

+1.40%

A

Agilent Technologies, Inc.

$120.40

+2.47%

NTRA

Natera, Inc.

$214.64

+6.31%

ILMN

Illumina, Inc.

$130.32

+2.65%

GH

Guardant Health, Inc.

$86.40

+5.10%

CRL

Charles River Laboratories International, Inc.

$179.31

+0.54%

TWST

Twist Bioscience Corporation

$57.41

+13.95%